AMANDA KIMMEL: Open Payments
NPI 1609461581 · TAMPA, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,556 in 133 payments from 37 companies in 2025. Trend: 2023 $1,601 · 2024 $3,993 · 2025 $3,556
Food & beverage: $2,840Long term medical supply or device loan: $716
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 17 | $879 |
| ABBVIE INC. | 9 | $284 |
| Celgene Corporation | 10 | $212 |
| PFIZER INC. | 8 | $180 |
| Merck Sharp & Dohme LLC | 8 | $171 |
| Gilead Sciences, Inc. | 7 | $162 |
| Janssen Biotech, Inc. | 6 | $139 |
| E.R. Squibb & Sons, L.L.C. | 6 | $122 |
| Astellas Pharma US Inc | 4 | $114 |
| GlaxoSmithKline, LLC. | 5 | $114 |
Products named: KISQALI, REBLOZYL, Trodelvy, KEYTRUDA, Vyloy, OJJAARA, VENCLEXTA, Lenvima.
Industry payments across FL — which companies pay providers there.
